GALT

Galectin Therapeutics Stock Analysis

AI Rating

Fair
  • Quality0/10
  • Growth↑ 6/10
  • Value↑ 6/10
Galectin Therapeutics sales and earnings growth
GALT Growth
Good
  • Revenue Y/Y↓ 0.00%
  • EPS Y/Y↑ 19.18%
  • FCF Y/Y↑ 9.07%
Galectin Therapeutics gross and profit margin trends
GALT Profitability
Low
  • Gross margin ↓ 0.00%
  • EPS margin↓ 0.00%
  • ROIC 5Y↓ -84.88%
Galectin Therapeutics net debt vs free cash flow
GALT Risk
Poor
  • Debt / Equity↑ 999.0
  • Debt / FCF↓ 3.6
  • Interest coverage↓ -4.2

Galectin Therapeutics stock is less volatile than the overall market, so it's low risk. We give it a Poor risk rating.

More Biotechnology stocks ↗